Objective: The optimal initial revascularization strategy remains uncertain for patients with peripheral arterial disease. The purpose of this study was to evaluate current nationwide selection and perioperative outcomes of patients undergoing bypass or endovascular intervention for infrainguinal disease in those with no prior ipsilateral revascularization.
The admission rate related to peripheral arterial disease (PAD) is rising, from approximately 480 per 100,000 U.S. population in 2003 to 710 in 2011. 1 Simultaneously, an increasing proportion of patients undergo revascularization in an attempt to relieve symptoms or to achieve limb preservation. Although there has been a national shift in revascularization procedures from open bypass to endovascular intervention, much controversy exists about the optimal initial management strategy for infrainguinal arterial disease. 2, 3 Evidence assessing the comparative effectiveness of both revascularization options has been hampered by the lack of randomized controlled trials, inclusion of previous ipsilateral failed procedures, and limited to small and regional retrospective series. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] This is reflected by the lack of vascular society practice guidelines. Whereas there is some consensus on the management for patients with claudication, 18 guidelines regarding the revascularization in chronic limb-threatening ischemia (CLTI) are still being developed in a collaboration between the Society for Vascular Surgery, the European Society for Vascular Surgery, and the World Federation of Vascular Societies as part of a new global consortium. In 2011, the American College of Cardiology Foundation/ American Heart Association published guidelines on PAD and concluded that both treatment strategies result in comparable mortality and limb amputation rates up to 1 to 2 years, albeit dependent on anatomic patterns of disease and severity. 19 The lack of consensus is further illustrated by the absence of clear recommendations from the TransAtlantic Inter-Society Consensus II (TASC II) committee with regard to a preferred revascularization strategy, 20 which has precluded publication of the planned TASC III document. Overall, endovascular intervention has been associated with lower periprocedural morbidity, whereas other studies have suggested superior long-term clinical durability after bypass. 21 The majority of these studies, however, did not compare outcomes after first-time procedures and included patients with failed prior ipsilateral treatment. This is a problem because several reports have suggested worse outcomes after repeated procedures. [22] [23] [24] Besides disease severity and anatomic characteristics, optimal treatment strategies are also determined by the patients' general health status before revascularization. Although case selection is clearly applied, in particular for patients with pre-existing conditions, well-defined patient characteristics that drive patient-centered decision-making are lacking.
Therefore, the purpose of our study was to identify nationwide patient characteristics associated with an endovascular-first approach and to assess perioperative outcomes of patients undergoing first-time infrainguinal revascularization in a large-scale, national registry.
METHODS
Data source. This is a retrospective cohort study using the 2011 to 2014 American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Targeted Vascular module. As a national clinical registry, NSQIP aims to improve surgical care by providing riskadjusted clinical outcomes in the first 30 days after the operative procedure. The targeted module greatly expands the variables collected and allows more tailored, disease-and procedure-specific analyses. In 2014, 83 centers contributed to the Targeted Vascular module. Clinical reviewers prospectively collect demographics, intraoperative details, and 30-day surgical outcomes in a standardized fashion according to NSQIP protocol. NSQIP methodology has been validated for data input accuracy, and regular quality assessments are performed through internal and external audits. [25] [26] [27] All data within NSQIP have been deidentified, and therefore approval was obtained from the Beth Israel Deaconess Medical Center Institutional Review Board and informed consent was waived.
Patients. All patients undergoing first-time infrainguinal bypass or endovascular intervention were used to create the cohort, excluding those with previous ipsilateral procedures. All emergent cases (n ¼ 316; 4.1%) and those undergoing hybrid procedures, namely, concomitant bypass and endovascular interventions (n ¼ 204; 2.7%), were excluded. To appropriately compare the relative effectiveness of both treatment options, we additionally excluded patients admitted for a femoraltibial/pedal bypass (n ¼ 1152; 15%) because an equivalent multilevel endovascular procedure was only infrequently documented in NSQIP. Femoral-tibial/pedal bypass was defined as a bypass originating from the femoral artery to distal outflow targets comprising the tibial or pedal arteries. As a result, we included only bypass procedures that were single level, that is, femoral to popliteal or popliteal to tibial/pedal; the latter were specified as tibial procedures. Next, the cohort was stratified by symptom status (CLTI or claudication), after which we classified patients into procedure type, isolated to the femoropopliteal or tibial segment. The type of revascularization was performed at the discretion of the treating physician. Stent placement during the endovascular procedure was not explicitly captured in this registry.
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Variables. Demographics, intraoperative characteristics, and 30-day postoperative outcomes were compared between endovascular-first and bypass-first patients. Bypass conduit types were categorized by NSQIP into the following two groups: (1) single-segment great saphenous vein or (2) prosthetic, arm vein, or composite grafts. Postoperative outcomes within 30 days of the intervention included mortality, major adverse limb event (MALE), major adverse cardiovascular event (MACE), minor amputation (below ankle), wound complications, bleeding, renal deterioration, respiratory complications, unplanned return to the operating room, secondary revascularizations, and any unplanned readmission. MALE was considered when one of the following was documented: ipsilateral major amputation, major surgical graft revision, new bypass, or use of thrombolysis or thrombectomy. 28 constructed multivariable logistic regression models stratified by symptom status. The predicted probability of undergoing an endovascular intervention was also determined, recognizing the additive effect of the obtained characteristics associated with this treatment modality. Additional multivariable logistic regression models were constructed to assess the independent associations between first-time procedures and 30-day outcomes. Covariates were selected using purposeful selection, incorporating backward selection after a univariate screen (P < .10) as well as including relevant patient factors previously identified. 29 Kaplan-Meier analysis was used to estimate unadjusted cumulative event rates, and treatments were compared using the log-rank test. Statistical analyses were conducted with SPSS Statistics 23 (IBM Corp, Armonk, NY), and figures were generated using Prism 6 (GraphPad, La Jolla, Calif). All tests were two tailed, and significance was considered when P < .05.
RESULTS
A total of 5998 patients underwent first-time infrainguinal revascularization and were included in this study. In the CLTI cohort of 3802 patients, 2010 (53%) were treated with a bypass-first approach (19% of these were tibial procedures) and 1792 (47%) with an endovascular-first approach (31% were tibial procedures). Among 2196 patients with claudication, 1183 (54%) underwent firsttime bypass (5% were tibial procedures) and 1013 (46%) first-time endovascular intervention (9% were tibial procedures).
Baseline characteristics in CLTI patients. Patient demographics and comorbidities were additionally stratified by procedure type and summarized in Table I , A (femoropopliteal) and B (tibial). For both femoropopliteal and tibial procedures, CLTI patients undergoing first-time endovascular intervention were older, less commonly smokers, and more likely functionally dependent; they more frequently suffered from preexisting conditions, such as diabetes, renal insufficiency, and current dialysis (all P < .05). Tissue loss was more common in CLTI patients treated with first-time endovascular intervention compared with bypass in both procedure types (femoropopliteal, 67% vs 57% [P < .001]; tibial, 86% vs 79% [P ¼ .01]).
Baseline characteristics in patients with claudication. Among patients with claudication undergoing femoropopliteal or tibial procedures, those with firsttime endovascular intervention were older, were less likely to be white, and more frequently suffered from diabetes compared with first-time bypass patients (Table I, A and B). In addition, among those with claudication and femoropopliteal disease, endovascularfirst patients less commonly smoked and suffered from chronic obstructive pulmonary disease, whereas they had more end-stage renal disease compared with bypass-first patients (all P < .05).
Intraoperative details in CLTI patients. In patients with CLTI undergoing first-time bypass, single-segment great saphenous vein conduits were more frequently used than prosthetic, arm vein, or composite grafts in femoropopliteal (56% vs 44%) and tibial (83% vs 17%) procedures. As detailed in Table II Postoperative outcomes in CLTI patients. Compared with a bypass-first approach, the rate of 30-day mortality after first-time endovascular intervention was comparable among CLTI patients (2.1% vs 2.2%; P ¼ .79 ;  Table III) . Similarly, MALE and major reintervention were equally distributed between both revascularization approaches (7.5% vs 6.8% [P ¼ .43] and 3.3% vs 4.3% [P ¼ 12], respectively). Although there was no significant difference in MACE, there was a trend toward lower cumulative rates after first-time endovascular intervention, particularly in the first 5 to 10 days after the procedure (log-rank, P ¼ .07; Fig 1) . In comparing first-time endovascular intervention with bypass, endovascular-first patients had significantly less surgical site infection (0.9% vs 7.7%; P < .001), bleeding (8.5% vs 17%; P < .001), respiratory complication (2.2% vs 3.7%; P < .01), and minor amputation (3.3% vs 4.8%; P ¼ .02) and a shorter total hospital stay (2 vs 6 days; P < .001). Whereas unplanned return to the operating room was less frequent after first-time endovascular intervention (13% vs 17%; P ¼ .001), there was a trend toward more secondary bypass or endovascular procedures within 30 days after first-time endovascular intervention (4.3% vs 3.1%; P ¼ .07). Moreover, major amputation occurred more frequently after an endovascular-first approach (4.6% vs 3.3%; P ¼ .04). Finally, CLTI patients treated with endovascularfirst intervention were more often discharged to home (86% vs 69%; P < .001).
Postoperative outcomes in patients with claudication. Among patients with claudication, mortality within 30 days did not differ significantly between endovascular-first and bypass-first patients (0.3% vs 0.6%; P ¼ .36), and neither did MALE (2.4% vs 1.9%; P ¼ .41) or major amputation (0.3% vs 0.3%; P > .99). Surgical site infections were less common after first-time endovascular intervention (0.7% vs 6.6%; P < .001), whereas bypass-first patients demonstrated a constantly increasing cumulative rate of infection from postoperative day 5 to day 30 (Fig 1) . Endovascular-first intervention was additionally associated with lower rates of bleeding (2.3% vs 6.0%; P < .001), respiratory complication (0.2% vs 0.9%; P ¼ .03), and unplanned readmission (5.9% vs 9.0%; P < .01) and a shorter total hospital stay (1 day vs 3 days; P < .001) compared with bypass first. Similar to CLTI patients, Multivariable analysis. With bypass-first patients as the reference group, we found comparable associations in patients with CLTI or claudication between an endovascular-first approach and several 30-day adverse outcomes (Table IV) . No significant association was found for mortality in CLTI patients (OR, 0.7; 95% CI, 0.4-1.1), whereas the death rate in those with claudication was too low for an adjusted analysis to be performed. Conversely, we found that endovascular-first intervention was an independent predictor of ipsilateral secondary bypass or endovascular procedures within 30 days postoperatively for CLTI (OR, 1.6; 95% CI, 1.04-2.3) but not for claudication (OR, 1.7; 95% CI, 0.9-3.4).
Current selection of patients. Independent factors associated with an endovascular-first as opposed to a bypass-first approach are displayed in Fig 2. Patient characteristics that could predict first-time endovascular intervention as a treatment modality in CLTI patients were age $80 years, tissue loss, nonsmoking, functional dependence, diabetes, current dialysis, and tibial lesions. Current factors associated with an endovascular intervention in patients with claudication included age $80 years, nonwhite race, nonsmoking, diabetes, and tibial lesions. The effect of these acquired factors was additive, with a predicted probability of being treated with an endovascular intervention of 62% in CLTI patients and 72% in those with claudication when four or more of these patient characteristics were present (Fig 3) .
DISCUSSION
This study demonstrates that 30-day morbidity, but not mortality, of patients treated with first-time endovascular intervention for infrainguinal arterial disease is substantially lower than that of bypass-first patients, despite their having more comorbidities. The endovascular treatment modality, however, was independently associated with higher rates of ipsilateral secondary revascularizations within 30 days, as these were 1.5 times more likely among patients with CLTI. In addition, in both patients with CLTI and patients with claudication, factors associated with an endovascular-first approach included patient demographics and anatomic characteristics as well as more severe, PAD-related comorbidities, such as diabetes and end-stage renal disease.
To date, only two randomized controlled trials have attempted to address the comparative effectiveness of both revascularization strategies in infrainguinal disease, 4, 5 yet these trials include previous ipsilateral interventions and are already considered outdated because of evolving endovascular techniques. The most prominent trial, the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial, was conducted between 1999 and 2004 in the United Kingdom and compared infrainguinal bypass with balloon angioplasty alone in 452 patients with severe limb ischemia. 4 Ultimately, the BASIL trial demonstrated no difference in mortality or amputationfree survival up to 2 years; however, in patients surviving >2 years, survival was higher in those who had bypass.
30
The 30-day mortality was comparable, with 5% in the bypass group and 3% in the angioplasty group, whereas bypass was associated with significantly higher morbidity (57% vs 41%). 4 The event rates were substantially higher than in this study, most likely related to several issues in study design, including no use of stents or drug-coated balloons in the angioplasty treatment group as well as the detrimental effects of repeated procedures, which limits the widespread applicability to first-time procedures. Although upcoming randomized trials, the BASIL-2 and Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI), will likely provide greater detail with respect to both treatment approaches, results will not be published for several years. 31, 32 Because these trials lack robust efficacy data and limit real-world generalizability, population-based observational studies may provide some guidance and new insights. In retrospective studies, there is a general consensus, reflected by a recent Vascular Quality Initiative study, that in 7897 revascularizations performed for CLTI, endovascular intervention was independently associated with lower 30-day mortality (OR, 0.6; 95% CI, 0.4-0.8) but worse 3-year survival (hazard ratio, 1.2; 95% CI, 1.1-1.4) compared with bypass surgery. 7 Similarly, Tsai et al 8 
reported in
1858 patients from community-based registries in Colorado and California that, using propensity analyses, those with CLTI or claudication treated with endovascular intervention were less likely to die within 30 days compared with bypass patients (0.2% vs 3.8%). However, contrary to the aforementioned study, patients who underwent endovascular intervention showed better survival rates as opposed to bypass during a follow-up period of 3 years. Our study may contribute to the current literature by demonstrating no differences in 30-day survival as opposed to the previous studies, which may have important clinical implications for first-time interventions because all prior studies included repeated procedures. Evidently, these prior procedures are affecting short-and long-term outcomes, which is supported by recent cohort studies. [22] [23] [24] There have been a handful of studies directly comparing first-time revascularizations. [11] [12] [13] 15 Although limited by small sample sizes and single-institution data, these studies also demonstrated comparable mortality and limb salvage data for both treatment approaches in patients with CLTI and claudication. The 30-day morbidity was additionally similar between first-time endovascular and bypass interventions, which is likely a result of low power in the majority of reports. Our recent single-institution study that included 1336 first-time procedures for CLTI also demonstrated that mortality (2.8% vs 3.3%) and transmetatarsal amputations (5% vs 4%) did not differ between endovascular-first and bypass-first patients, although the unadjusted and adjusted 3-year survival and freedom from restenosis and reintervention were better for bypass-first patients. 13 As a national representation of first-time infrainguinal interventions, this study may function as a useful adjunct to patient-centered decision-making by weighing risks and benefits of perioperative morbidity against reinterventions in patients with multiple comorbidities. A comparison of adverse postoperative events between first-time endovascular intervention and bypass is complicated by the prevalence and diversity of pre-existing conditions. However, as length of stay was shorter and the incidence of postoperative complications (eg, cardiac and wound complications) and unplanned readmissions were lower among those undergoing endovascular intervention despite comorbidities being more pronounced, this study further supports the benefits of first-time endovascular intervention over bypass in the perioperative period and for those with a relatively short life expectancy. Factors used to select the method of revascularization are heterogeneous and may differ per institution and physician, but they may also change over time with increased experience and adoption of novel techniques and approaches. This study determined current nationwide selection of patients for first-time endovascular intervention in the United States, and we found that older patients as well as those with more severe comorbidities and tibial disease were more likely candidates to undergo an endovascular-first approach. One other retrospective cohort study used patient characteristics to predict the probability of undergoing revascularization in 1200 German patients with CLTI. 16 The authors concluded that the probability of being treated with bypass was noticeably higher with normal renal function, current smokers, previous failed interventions, TASC C or D lesions, and three runoff vessels. Although this study found, in part, similar characteristics, NSQIP lacks specificity, such as detailed anatomic and lesion data, and therefore confounding by indication may influence these results. However, awareness of these patient characteristics is relevant to both the physician and patient for identifying the optimal type of treatment and for development of realistic expectations based on nationwide experiences. There are some additional limitations to this study. As a retrospective study, the potential for treatment selection bias exists because our data were subject to the experience and preferences of the providers. Furthermore, the Targeted Vascular module consists of a randomly selected subset of patients from participating hospitals nationwide, and as a result, the proportion of patients undergoing one or both revascularization approaches may not be representative of all practices. Despite adjusting for a number of covariates in our multivariable models, within NSQIP we were limited by predefined variables recorded in this registry as well as by unmeasured confounders, such as extent of arterial lesion and wound severity. In addition, 5% of patients with claudication in our cohort underwent a popliteal to tibial/pedal bypass, and although this remains a controversial topic, it is possible that the symptom status of some of these patients was miscoded. Finally, we attempted to account for extent of disease by separating femoropopliteal and tibial disease, but lesion data would have added great detail to our patient selection model and comparison of both treatment strategies.
CONCLUSIONS
This study demonstrates the early morbiditydbut not mortalitydbenefit of endovascular intervention over bypass in first-time infrainguinal revascularizations, although more postoperative secondary revascularizations were performed after an endovascular-first approach. As more patients undergo revascularization, there remains a lack of evidence to support a clear advantage of either approach over the other. Accepting these limitations, this study highlights the early perioperative benefits of an endovascular-first strategy, but more robust data on long-term outcomes in select PAD patients are needed before this can be recommended as the therapy of choice. Boldface P values represent significance (P < .05).
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